Day: August 6, 2022

Beam Global Schedules Fiscal Second Quarter 2022 Financial Results Conference Call for August 12, 2022 at 4:30 p.m. ET

Beam Global Schedules Fiscal Second Quarter 2022 Financial Results Conference Call for August 12, 2022 at 4:30 p.m. ET

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM, BEEMW), (the “Company”), the leading provider of innovative sustainable products and technologies for electric vehicle (EV) charging, energy storage, energy security and outdoor media, announced that it will report its Fiscal Second Quarter 2022 financial results on Friday August 12, 2022. Management will host a conference call on Friday August 12, 2022 at 4:30 p.m. ET to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session. Conference call details: Date:         August 12, 2022Time:         4:30 p.m. Eastern/1:30 p.m. PacificToll-Free Dial-In Number:    1-844-739-3880International Dial-In Number:    1-412-317-5716 Pre-register for the call through this link:...

Continue reading

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediately Myovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, Switzerland and NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain...

Continue reading

Algoma Steel Tables Revised Best and Final Offer in Collective Agreement Negotiations with USW Local 2251

Algoma Steel Tables Revised Best and Final Offer in Collective Agreement Negotiations with USW Local 2251

USW Local 2251 Refuses to Take it to a Vote SAULT STE. MARIE, Ontario, Aug. 05, 2022 (GLOBE NEWSWIRE) — Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or the “Company”) announced today that the Company has submitted a revised best and final Collective Bargaining Agreement (“CBA”) offer to the Negotiating Committee of United Steelworkers Local Union 2251 (“2251”), the union representing Algoma’s hourly employees. Algoma has again received notice that the 2251 Negotiating Committee has refused the offer and is unwilling to bring the offer to employees for a vote. Algoma believes its offer to 2251 provides a highly competitive compensation package that is superior to many of the Company’s peers in the industry and includes numerous health and wellness benefit enhancements and protections offered by the Company in an effort...

Continue reading

Imperial Announces $45 Million Non-Brokered Private Placement of Convertible Debentures

Imperial Announces $45 Million Non-Brokered Private Placement of Convertible Debentures

VANCOUVER, British Columbia, Aug. 05, 2022 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) announces its intention to secure additional financing for the restart of the Mount Polley Mine by way of a non-brokered private placement of $45 million aggregate principal amount of convertible debentures (the “Convertible Debentures”). The Mount Polley mine is currently operating at targeted production rates. However, the restart took longer than planned due to difficulties in hiring operating personnel, supply chain challenges and unanticipated electrical and mechanical work. This, together with lower copper prices, caused a shortfall in revenues compared to budget. In addition, the rights offering was not fully subscribed resulting in a shortfall in budgeted equity financing. Due to these reasons, the Company...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.